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The hypothesis that abnormal BH4
metabolism impairs kidney function
To the Editor: Sucher reported that BH4 has a protective
effect against acute renal failure.1 We reported that the
BH4/dihydrobiopterin (BH2) ratio was signiﬁcantly lower in
hemodialysis patients (0.26±0.06) than in controls
(1.15±0.11).2 This indicates that the reduction of quino-
noid-type BH2 to BH4 is decreased in patients with chronic
renal failure. BH4 is similar to ascorbic acid, in that its
reduced form is an antioxidant and there is an increase of the
oxidized form in renal failure. These alterations of BH4
metabolism might have a role in the decrease of constitutive
endothelial nitric oxide synthase activity. As kidney function
worsens, the disorder of BH4 metabolism increases.
2
It is well known that signiﬁcant ablation of the renal mass
initiates a cycle of progressive glomerular injuries in the remnant
kidney tissue. This process is associated with glomerular
hypertrophy, hyperﬁltration, and systemic hypertension. It is
also known that a plot of 1/creatinine (Cr) versus time shows a
linear relationship in patients with chronic kidney disease, which
is the mathematical expression of nephron loss.3
However, the above-mentioned linear relationship is not
related to the histological type of renal disease. In other words,
it also occurs in renal diseases that are not associated with
hyperﬁltration. Based on the above points, the hypothesis that
aggravation of renal failure can be predicted by the linear
relationship of 1/Cr with time might indicate that renal failure
itself makes renal failure. Metabolic derangement of BH4 might
have a role in the progression of renal failure (Figure 1).
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The Authors Reply: We thank Drs Yokoyama and Hosoya1
for highlighting the fact that not only is BH4 deﬁciency a
signiﬁcant contributor to acute renal failure, as recently
shown by our group in Kidney International, but also a
decreased reduction rate of quinonoid-type BH2 (BH4/
dihydrobiopterin ratio) to BH4 is found in patients with
chronic renal failure.2,3 Such changes in BH4 metabolism
might signiﬁcantly alter nitric oxide synthase (NOS) activity.
In particular, an increase in the oxidized form of BH4 and
hence a lack of antioxidant function contribute to impaired
renal function in the long term.
The vicious cycle that is initiated by loss of renal mass/BH4
and consecutive uncoupling of NOS has been clearly shown to
result in both increased formation of O2
 by NOS and reduced
overall nitric oxide (NO) production. This free radical imbalance
is considered to be one of the main contributing factors to the
establishment of atherosclerosis, hypertension, and vascular
dysfunction subsequent to renal failure.4
In addition, changes in NO-mediated gene expression due
to altered BH4 levels can induce expression of genes related to
inﬂammation and ﬁbrosis and thereby further contribute to
chronic renal damage.5
Consequently, it is scientiﬁcally rewarding to see that the
substitution of BH4 to restore NO levels and free radical
balance as shown in multiple small and large animal models,
including our own most recent work, offers a promising
clinical strategy to ameliorate both acute and chronic renal
failure that warrants intense further investigation.
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Figure 1 | The traces plotted as 1/creatinine (Cr) versus time
from patients with chronic kidney disease are linear.
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